Suppr超能文献

心力衰竭患者肠道微生物生成的代谢产物氧化三甲胺水平升高的预后价值:完善肠道假说

Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis.

作者信息

Tang W H Wilson, Wang Zeneng, Fan Yiying, Levison Bruce, Hazen Jennie E, Donahue Lillian M, Wu Yuping, Hazen Stanley L

机构信息

Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio; Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio.

Department of Cellular and Molecular Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

出版信息

J Am Coll Cardiol. 2014 Nov 4;64(18):1908-14. doi: 10.1016/j.jacc.2014.02.617. Epub 2014 Oct 27.

Abstract

BACKGROUND

Altered intestinal function is prevalent in patients with heart failure (HF), but its role in adverse outcomes is unclear.

OBJECTIVES

This study investigated the potential pathophysiological contributions of intestinal microbiota in HF.

METHODS

We examined the relationship between fasting plasma trimethylamine-N-oxide (TMAO) and all-cause mortality over a 5-year follow-up in 720 patients with stable HF.

RESULTS

The median TMAO level was 5.0 μM, which was higher than in subjects without HF (3.5 μM; p < 0.001). There was modest but significant correlation between TMAO concentrations and B-type natriuretic peptide (BNP) levels (r = 0.23; p < 0.001). Higher plasma TMAO levels were associated with a 3.4-fold increased mortality risk. Following adjustments for traditional risk factors and BNP levels, elevated TMAO levels remained predictive of 5-year mortality risk (hazard ratio [HR]: 2.2; 95% CI: 1.42 to 3.43; p < 0.001), as well as following the addition of estimated glomerular filtration rate to the model (HR: 1.75; 95% CI: 1.07 to 2.86; p < 0.001).

CONCLUSIONS

High TMAO levels were observed in patients with HF, and elevated TMAO levels portended higher long-term mortality risk independent of traditional risk factors and cardiorenal indexes.

摘要

背景

肠道功能改变在心力衰竭(HF)患者中很常见,但其在不良结局中的作用尚不清楚。

目的

本研究调查了肠道微生物群在HF中的潜在病理生理作用。

方法

我们在720例稳定HF患者中进行了为期5年的随访,研究空腹血浆三甲胺-N-氧化物(TMAO)与全因死亡率之间的关系。

结果

TMAO水平中位数为5.0μM,高于无HF的受试者(3.5μM;p<0.001)。TMAO浓度与B型利钠肽(BNP)水平之间存在适度但显著的相关性(r=0.23;p<0.001)。较高的血浆TMAO水平与死亡风险增加3.4倍相关。在对传统危险因素和BNP水平进行调整后,TMAO水平升高仍然可预测5年死亡风险(风险比[HR]:2.2;95%CI:1.42至3.43;p<0.001),在模型中加入估计肾小球滤过率后也是如此(HR:1.75;95%CI:1.07至2.86;p<0.001)。

结论

在HF患者中观察到高TMAO水平,且TMAO水平升高预示着更高的长期死亡风险,独立于传统危险因素和心肾指标。

相似文献

4
Trimethylamine N-oxide and prognosis in acute heart failure.
Heart. 2016 Jun 1;102(11):841-8. doi: 10.1136/heartjnl-2015-308826. Epub 2016 Feb 11.
7
Trimethylamine N-oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction.
ESC Heart Fail. 2020 Feb;7(1):188-193. doi: 10.1002/ehf2.12552. Epub 2020 Jan 20.
8
Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide.
Eur Heart J. 2014 Apr;35(14):904-10. doi: 10.1093/eurheartj/ehu002. Epub 2014 Feb 3.
10
Trimethylamine N-Oxide and Mortality Risk in Patients With Peripheral Artery Disease.
J Am Heart Assoc. 2016 Oct 19;5(10):e004237. doi: 10.1161/JAHA.116.004237.

引用本文的文献

1
Role of gut microbiota and derived metabolites in cardiovascular diseases.
iScience. 2025 Jul 30;28(9):113247. doi: 10.1016/j.isci.2025.113247. eCollection 2025 Sep 19.
4
Research Trends and Hotspots of Gut Microbiota and Its Metabolites in Cardiovascular Diseases: A Bibliometric Analysis.
J Multidiscip Healthc. 2025 Aug 21;18:5125-5145. doi: 10.2147/JMDH.S533730. eCollection 2025.
5
Decoding the impact of gut microbiota on heart failure.
Genes Dis. 2025 Mar 6;12(6):101592. doi: 10.1016/j.gendis.2025.101592. eCollection 2025 Nov.
7
Gut microbiota's role in heart failure.
Heart Fail Rev. 2025 Jul 9. doi: 10.1007/s10741-025-10543-w.
10
The Interplay of Cross-Organ Immune Regulation in Inflammation and Cancer.
MedComm (2020). 2025 Jun 15;6(7):e70249. doi: 10.1002/mco2.70249. eCollection 2025 Jul.

本文引用的文献

1
Muscle wasting: the gut microbiota as a new therapeutic target?
Int J Biochem Cell Biol. 2013 Oct;45(10):2186-90. doi: 10.1016/j.biocel.2013.06.021. Epub 2013 Jul 4.
2
Clinical characteristics, morbidity, and prognostic value of concomitant coronary artery disease in idiopathic dilated cardiomyopathy.
Clin Res Cardiol. 2013 Oct;102(10):771-80. doi: 10.1007/s00392-013-0589-7. Epub 2013 Jun 26.
3
Abdominal contributions to cardiorenal dysfunction in congestive heart failure.
J Am Coll Cardiol. 2013 Aug 6;62(6):485-95. doi: 10.1016/j.jacc.2013.04.070. Epub 2013 Jun 7.
4
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.
N Engl J Med. 2013 Apr 25;368(17):1575-84. doi: 10.1056/NEJMoa1109400.
5
Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis.
Nat Med. 2013 May;19(5):576-85. doi: 10.1038/nm.3145. Epub 2013 Apr 7.
6
The role of uric acid in the pathogenesis of human cardiovascular disease.
Heart. 2013 Jun;99(11):759-66. doi: 10.1136/heartjnl-2012-302535. Epub 2013 Jan 23.
7
Host-gut microbiota metabolic interactions.
Science. 2012 Jun 8;336(6086):1262-7. doi: 10.1126/science.1223813. Epub 2012 Jun 6.
9
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease.
Nature. 2011 Apr 7;472(7341):57-63. doi: 10.1038/nature09922.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验